Elevated admission inflammatory markers, specifically Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), Monocyte-to-Lymphocyte Ratio (MLR), and Systemic Immune-Inflammation Index (SII), are robust predictors of 6-month functional disability (mRS 3–6) in CVT patients.
PLR and SII demonstrate particularly high prognostic value for mortality, with PLR >161.04 associated with a seven-fold increase in 6-month mortality risk.
A systematic review of nearly 19,000 patients confirms that NLR is among the most frequently reported and statistically significant blood-based biomarkers for predicting CVT outcomes.
Despite their prognostic utility, these markers do not appear to correlate with early venous recanalization or the radiological evolution of brain lesions, suggesting they reflect systemic stress or the underlying pathophysiology of neuro-inflammation.
